---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038161"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:49:19.038134+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Apogee Therapeutics doses first volunteers in Phase 1 trial of APG808 for COPD and asthma

## Summary
- First participants dosed in Phase 1 healthy volunteer trial of APG808, a half-life extended IL-4Rα mAb.
- Preclinical data suggest potential for dosing every 6-8 weeks vs. every 2 weeks for other biologics in development.
- Interim safety and PK data from healthy volunteers anticipated in second half of 2024.
- APG808 is the second product candidate to enter clinic, following positive interim results from Phase 1 trial of APG777.
- Company plans to initiate Phase 1b asthma trial in 1H 2025 and Phase 2 COPD trial in 2025, pending positive Phase 1 results.

## SEC filing metadata
- accession: 0001104659-24-038161
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924038161/0001104659-24-038161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924038161/tm249632d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038161
- JSON: https://secwatch.observer/filing/0001104659-24-038161.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.